文献速递慢阻肺

两阶段风险分层策略:FEV1/FEV6联合CDQ用于慢阻肺病例发现

A Two-Staged, Risk-Stratified Strategy Combining FEV1/FEV6 and COPD Diagnostic Questionnaire Acts as an Accurate and Cost-Effective COPD Case-Finding Method.
PubMed 文献 · Respirology · 2025-02-11

该横断面前瞻性观察研究纳入224例≥40岁、有呼吸道症状且吸烟≥10包年的参与者,比较手持肺功能设备与问卷组合对慢阻肺的诊断准确性。结果显示FEV1/FEV6联合CDQ的AUROC最高(0.903),并据此提出两阶段风险分层策略,可减少误诊并节省成本和时间,但需外部验证。

要点

  • FEV1/FEV6单独诊断慢阻肺的AUROC为0.888,优于问卷和PEFR。
  • CDQ联合FEV1/FEV6的AUROC达0.903,为最高诊断准确性组合。
  • 两阶段策略:CDQ≤13无需进一步检查,CDQ 14-26查FEV1/FEV6,CDQ≥27或中危且FEV1/FEV6<0.76行确诊肺功能。

核心结论

  • FEV1/FEV6与CDQ联合达到最高诊断准确性,两阶段风险分层策略可准确且经济地发现未诊断的慢阻肺高危个体。

研究设计与样本

  • 横断面、前瞻性、观察性研究,纳入224例年龄≥40岁、有呼吸道症状且吸烟≥10包年的参与者。
  • 参与者完成三种问卷(CDQ、肺功能问卷、COPD人群筛查器)和两种手持肺功能设备(峰流速仪、微型肺量计),后行肺功能确诊慢阻肺(支气管舒张后FEV1/FVC<0.7)。

主要发现

  • 224例参与者中慢阻肺发生率为29%。
  • 问卷AUROC为0.678-0.69,PEFR为0.807,FEV1/FEV6为0.888;手持设备诊断准确性显著高于问卷(两两比较p<0.05)。
  • 基于FEV1/FEV6的组合AUROC为0.897-0.903,优于基于PEFR的组合(0.810-0.818;p<0.05)。
  • CDQ与FEV1/FEV6组合的AUROC最高(0.903),FEV1/FEV6最佳截断值为<0.76。
  • 两阶段策略敏感度/特异度为0.82/0.84。

关键数值与推荐

  • 低危(CDQ≤13)无需进一步检查;中危(CDQ 14-26)应行FEV1/FEV6;高危(CDQ≥27)及中危且FEV1/FEV6<0.76者需确诊性肺功能检查。
  • FEV1/FEV6<0.76为最佳截断值。

临床怎么用

  • 可先以CDQ进行风险分层,低危者避免进一步检查,中危者行FEV1/FEV6,高危或中危且FEV1/FEV6<0.76者行确诊性肺功能。
  • 该策略相比单独FEV1/FEV6可减少误诊并节省成本和时间。

局限性

  • 需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Symptom-based questionnaires and handheld lung function devices are widely used for COPD case finding, but the optimal combination remains unclear. This study aimed to compare the diagnostic accuracy (DA) of various combinations of handheld lung function devices and questionnaires and develop a COPD case-finding strategy. METHODS: This cross-sectional, prospective, observational study enrolled participants aged ≥ 40 years with respiratory symptoms and ≥ 10 smoking pack-years. Participants completed three questionnaires (COPD diagnostic questionnaire [CDQ], lung function questionnaire; COPD Population Screener) and 2 handheld lung function devices (peak flow meter, microspirometer), followed by spirometry to confirm COPD (post-bronchodilation FEV1/FVC < 0.7). DA is assessed using the area under the ROC curve (AUROC). RESULTS: Among 224 participants, COPD incidence was 29%. Individually, handheld devices showed significantly higher DA than questionnaires (AUROC 0.678-0.69 for questionnaires vs. 0.807 for peak expiratory flow rate [PEFR] and 0.888 for FEV1/FEV6; all pairwise p < 0.05). FEV1/FEV6-based combinations outperformed PEFR-based combinations (all n = 224; AUROC 0.897-0.903 vs. 0.810-0.818; p < 0.05). The CDQ and FEV1/FEV6 combination reached the highest DA (AUROC 0.903). FEV1/FEV6 < 0.76 was the optimal cutoff value. A two-staged strategy (sensitivity/specificity 0.82/0.84) was proposed: low-risk participants (CDQ ≤ 13) need no further testing; middle-risk (CDQ 14-26) should undergo FEV1/FEV6; and high-risk (CDQ ≥ 27) and middle-risk with FEV1/FEV6 < 0.76 require confirmatory spirometry. This approach would reduce misdiagnoses and save costs and time compared to FEV1/FEV6 alone. CONCLUSION: FEV1/FEV6 and CDQ combination achieves the highest DA. A two-staged, risk-stratified strategy combining CDQ and FEV1/FEV6 can be accurate and cost-effective to detect at-risk, undiagnosed COPD subjects. External validation is required.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Lo PC, Ko HK, Chou KT, et al. A Two-Staged, Risk-Stratified Strategy Combining FEV1/FEV6 and COPD Diagnostic Questionnaire Acts as an Accurate and Cost-Effective COPD Case-Finding Method. Respirology. 2025. PMID: 39933794. doi:10.1111/resp.70000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。